Recombinant adeno-associated viral (rAAV) vectors have shown early promise in clinical trials 1-3 . The therapeutic transgene cassette can be packaged in different AAV capsid pseudotypes, each having a unique transduction profile. At present, rAAV capsid serotype selection for a specific clinical trial is based on effectiveness in animal models. However, preclinical animal studies are not always predictive of human outcome [4] [5] [6] [7] [8] . Here, in an attempt to further our understanding of these discrepancies, we used a chimaeric human-murine liver model to compare directly the relative efficiency of rAAV transduction in human versus mouse hepatocytes in vivo. As predicted from preclinical and clinical studies 4,5,8 , rAAV2 vectors functionally transduced mouse and human hepatocytes at equivalent but relatively low levels. However, rAAV8 vectors, which are very effective in many animal models, transduced human hepatocytes rather poorlyapproximately 20 times less efficiently than mouse hepatocytes. In light of the limitations of the rAAV vectors currently used in clinical studies, we used the same murine chimaeric liver model to perform serial selection using a human-specific replication-competent viral library composed of DNA-shuffled AAV capsids. One chimaeric capsid composed of five different parental AAV capsids was found to transduce human primary hepatocytes at high efficiency in vitro and in vivo, and provided species-selected transduction in primary liver, cultured cells and a hepatocellular carcinoma xenograft model. This vector is an ideal clinical candidate and a reagent for gene modification of human xenotransplants in mouse models of human diseases. More importantly, our results suggest that humanized murine models may represent a more precise approach for both selecting and evaluating clinically relevant rAAV serotypes for gene therapeutic applications.
Recombinant adeno-associated viral (rAAV) vectors have shown early promise in clinical trials [1] [2] [3] . The therapeutic transgene cassette can be packaged in different AAV capsid pseudotypes, each having a unique transduction profile. At present, rAAV capsid serotype selection for a specific clinical trial is based on effectiveness in animal models. However, preclinical animal studies are not always predictive of human outcome [4] [5] [6] [7] [8] . Here, in an attempt to further our understanding of these discrepancies, we used a chimaeric human-murine liver model to compare directly the relative efficiency of rAAV transduction in human versus mouse hepatocytes in vivo. As predicted from preclinical and clinical studies 4, 5, 8 , rAAV2 vectors functionally transduced mouse and human hepatocytes at equivalent but relatively low levels. However, rAAV8 vectors, which are very effective in many animal models, transduced human hepatocytes rather poorlyapproximately 20 times less efficiently than mouse hepatocytes. In light of the limitations of the rAAV vectors currently used in clinical studies, we used the same murine chimaeric liver model to perform serial selection using a human-specific replication-competent viral library composed of DNA-shuffled AAV capsids. One chimaeric capsid composed of five different parental AAV capsids was found to transduce human primary hepatocytes at high efficiency in vitro and in vivo, and provided species-selected transduction in primary liver, cultured cells and a hepatocellular carcinoma xenograft model. This vector is an ideal clinical candidate and a reagent for gene modification of human xenotransplants in mouse models of human diseases. More importantly, our results suggest that humanized murine models may represent a more precise approach for both selecting and evaluating clinically relevant rAAV serotypes for gene therapeutic applications.
rAAV clinical trials have been hampered by unanticipated immunological responses and lower than expected levels of transgene product [5] [6] [7] [8] . For a single serotype there is little correlation between in vitro and in vivo transduction of primary cells. Between two serotypes, AAV8 and AAV2, the former provides .10-fold higher levels of liver-mediated gene transfer in animals, including non-human primates 6, [9] [10] [11] . An exception may be humans, where in the case of haemophilia B 6 the peak level of factor IX transgene product was similar in rAAV2-and rAAV8treated individuals 8 . There are many potential reasons for the observed discordance in gene transfer efficiency among species, but relatively small differences in capsid sequence can affect both cellular uptake and postcell-entry processing between species, ultimately affecting the level of gene transfer 12 .
To establish if murine and human hepatocytes contained within the context of an intact liver are themselves differentially transduced, we injected Fah 2/2 /Rag2 2/2 /Il2rg 2/2 (FRG) mice 13 partially repopulated with primary human hepatocytes (hFRG) with single-stranded or selfcomplementary rAAV2 and rAAV8 vectors expressing enhanced green fluorescent protein (eGFP) ( Fig. 1a, b ). rAAV2 administration resulted in a low but equal number of eGFP-positive mouse and human hepatocytes. However, the rAAV8 vector resulted in a ,20fold higher transduction efficiency in mouse compared with human hepatocytes, consistent with differences observed in preclinical and clinical studies published so far [6] [7] [8] 10, 11 . The block to functional rAAV8 transduction in human cells was not due to a lack of viral binding/ uptake in the human hepatocytes because vector genomes were near equal in both human and mouse hepatocytes, as measured by quantitative polymerase chain reaction (qPCR) after laser capture microscopy (LCM) ( Fig. 1c ). By contrast, the rAAV2 vector genomes were preferentially taken up by human hepatocytes even though gene expression was similar in both the mouse and human cells. These results strongly suggest that differential functional transduction (measured as transgene expression) between capsid serotypes and species can be dependent on post-uptake factors.
Many different approaches have been used to alter the viral capsid and hence vector transduction properties [14] [15] [16] [17] [18] [19] [20] [21] . As our goal was to identify new capsids with improved human tissue transduction, we created and screened a replicating AAV capsid library in the humanized mouse liver model. Our library screens are different from most in that selection is dependent not only on viral uptake and internalization, but also on viral replication, allowing us to select for these important post-uptake parameters that can affect vector-mediated gene transfer (reviewed in ref. 22) .
Ten AAV capsid genes (AAV1, 2, 3B (ref. 23), 4, 5, 6, 8, 9, avian and bovine AAV) were used to generate an AAV-shuffled library (see Methods). To perform virus selection in vivo we used FRG mice partially repopulated with primary human hepatocytes (see Methods). Because the AAV libraries co-infected with wild-type human adenovirus 5 (hAd5) do not replicate in mice 14 , we have a stringent simultaneous positive and negative selection between the human and murine cells, respectively.
We performed four rounds of selection ( Fig. 2a ) and monitored progress by sequencing .100 clones after each round ( Fig. 2b ). Library selection in non-humanized FRG animals in the presence of hAd5 served as a negative control and confirmed that rescued AAV was derived from the human cells ( Fig. 2b) , whereas a non-humanized FRG animal injected with hAd5 only served as a control to ensure that AAV capspecific PCR signals were not caused by wild-type/rAAV contamination of the hAd5 preparation ( Fig. 2a, b ). After four rounds, the three most frequent variants, AAV-LK01, -LK02 and -LK03, accounted for 22.7%, 4.54% and 2.3% of the isolates, respectively. From the 19 most abundant variants, 15 were successfully used to package vectors, rAAV-RSV-eGFP (RSV, Rous sarcoma virus) ( Fig. 2c ). Reconstruction of the genealogical relationship at the DNA and amino acid level between the isolates and parental AAVs used to generate the library is shown in Fig. 2d We compared the in vitro transduction of these 15 AAV vector variants against standard AAV serotypes on a variety of cell types from different species (Extended Data Table 1 ). In comparison to rAAV-DJ, which efficiently transduces most mouse and human cells in culture 14 , rAAV-LK03 preferentially transduced cells of human origin, suggesting that this variant has species-restricted specificity. Importantly, rAAV-LK03 transduced primary human hepatocytes 100-fold better than AAV8. AAV-LK03 is closely related to AAV3B, with lesser contributions from AAV1, 2, 4, 6, 8 and 9 (Figs 2d and 3a, Extended Data Table 2 , Supplementary Table 1 and Supplementary Figs 1 and 2) . rAAV-LK03 transduced human hepatocytes in culture 3, 67 and 6.5 times more efficiently than rAAV-DJ, rAAV8 and rAAV3B, respectively (Fig. 3b) .
A second isolate, AAV-LK19, differed from AAV-LK03 by a single amino acid, S262C. This isolate transduced mouse cell lines and was less efficient than rAAV-LK03 at transducing most human cells, with the exception of primary human keratinocytes, where AAV-LK19 resulted in 5 and 7.6 times higher levels compared with rAAV-LK03 and rAAV6, the serotype reported to transduce human keratinocytes 24 , respectively (Extended Data Table 1 ).
As pre-existing humoral immunity can block the clinical efficacy of a vector 8 , we tested selected AAVs in a pooled human immunoglobulin-G (IVIG) neutralization assay (Extended Data Fig. 1 and Methods). Compared with AAV2, AAV3B, AAV-LK03 and AAV-LK19 were much more resistant to IVIG neutralization ( Fig. 3c ), suggesting that these vectors could transduce a large population of humans if used in a clinical trial 25, 26 .
Owing to the similarity between AAV-LK03, -LK19 and AAV3B, we wanted to establish whether the human hepatocyte growth factor (hHGF) receptor c-MET, previously identified as the AAV3 co-receptor 27 , was involved in AAV-LK03 and -LK19 transduction. Transduction of Huh-7 cells with rAAV-hPGK-GFP-P2A-Luc2 (Luc2, luciferase 2) in the presence of increasing concentrations of hHGF (used for c-MET competition) demonstrated that rAAV-LK03, but not rAAV-LK19, was competitively inhibited by hHGF ( Fig. 3d ). These results suggest that the single amino acid difference (S262C) changes the receptor/co-receptor entry of AAV-LK19. Although the AAV capsid structure is available for several serotypes, the bulk of the sequence variation in these two new pseudotypes was in VP1 (amino acids 1-125), the one region of the capsid for which the structure has yet to be determined, making it difficult to speculate on specific structure-function relationships.
To compare the relative effectiveness of selected AAVs for transgene expression in vivo, we selected eight serotypes to package the hFIX expression cassette used in the rAAV2-FIX clinical trial 8 . In mice, the rAAV-LK03 and rAAV-LK19 vectors expressed very low levels of hFIX ( Fig. 3e ). By contrast, rAAV-LK01 and rAAV-LK02, which are closely related to AAV8 and AAV9, and AAV1 and AAV6, respectively ( Fig. 2d ), provided similar levels of expression as that observed with rAAV-DJ and rAAV8. Liver vector copy number (VCN) analysis performed 54 days after vector administration (Extended Data Fig. 2a ) correlated with the hFIX expression data: rAAV8 . rAAV-LK02 < rAAV-DJ ? rAAV-LK03. Furthermore, liver AAV VCN determined at an early time point (Extended Data Fig. 2b ) also correlated with transgene expression (Extended Data Fig. 2c ), suggesting that rAAV-LK03 did not enter murine hepatocytes and/or was rapidly degraded upon cell entry.
To verify the strong species preference, we tested rAAV-LK03 in a hepatocellular carcinoma xenograft model 28 . Animals injected with rAAV3B showed no Luc expression in the liver or tumour, whereas animals injected with rAAV8 showed Luc expression from the tumour and the liver ( Fig. 4a and Supplementary Figs 3, 4 ). Consistent with the data obtained with rAAV-hFIX in normal mice ( Fig. 3e and Extended Data Fig. 2c ), animals treated with rAAV-LK03-RSV-Luc2 did not show a detectable Luc signal from the liver but only from human tumours. In addition, the onset of transgene expression from AAV-LK03 was slower by about 48 h compared to AAV8 (Extended Data Fig. 3 ).
Having demonstrated that AAV-LK03 selectively transduced human cells, we next evaluated its transduction efficiency in FRG mice 
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with and without human hepatocyte reconstitution (Fig. 4b) . In agreement with previously published data 27 , rAAV3B did not transduce murine hepatocytes (control animals in Fig. 4b and Extended Data Fig. 4) . Surprisingly, rAAV3B, previously shown to transduce human hepatocytes in culture 27 (Fig. 3b ), did not lead to detectable Luc expression in engrafted human hepatocytes in this in vivo model. By contrast, a strong Luc signal was detected in non-humanized FRG animals injected with rAAV8-RSV-Luc ( Fig. 4b and Extended Data Fig. 4 ), which efficiently transduced mouse hepatocytes in vivo ( Fig. 3e and Extended Data Fig. 2 ). Most importantly, as predicted, the Luc signal was detected in humanized FRG mice injected with rAAV-LK03, but not in non-humanized FRG controls. These data showed that rAAV-LK03 selectively transduces human hepatocytes in vivo.
To quantify further the transduction efficiency of rAAV-LK03, we injected an equal dose of rAAV-LK03 or rAAV8-eGFP into humanized FRG mice. One week later, the number of transduced cells was compared (Fig. 4c ). The fraction of GFP-positive human hepatocytes was 43.3 6 11% and 3.6 6 1.1% with rAAV-LK03 and AAV8 vector infusion, respectively. By contrast, almost all (.99%) mouse hepatocytes were eGFP positive with rAAV8, whereas =1% of mouse hepatocytes were eGFP positive after rAAV-LK03 vector infusion. Thus, rAAV-LK03 transduction, as measured by the number of transgene-positive cells, was about ten times higher than AAV8 in human hepatocytes in vivo. This experiment may underestimate the differences in AAVmediated human hepatocyte transduction because of the variation in the rate of capsid uncoating and peak transgene expression among different serotypes. Whereas rAAV8 is rapidly uncoated 29 , longer uncoating for rAAV-LK03 can be inferred from the slower rise in transgene expression in the tumour xenotransplant transduction studies (Extended Data Fig. 3 ).
The fact that there was not always a correlation between vector uptake and transgene expression between species (Fig. 1 ) strongly suggests that post-receptor entry factors (such as intracellular transport, nuclear entry and/or uncoating) influence the final level of functional transduction (reviewed in ref. 12) . By making replication in human cells a condition for selection, we placed selection pressure on many of these post-entry parameters. Moreover, the human primary hepatocytes were in an environment that emulated their native Controls, naive animals. The same results were observed in two independent biological repeats. b, Luc expression in humanized FRG animals (hFRG) or naive controls (Ctr). Serum human albumin (hAlb) levels and estimated percentages of human hepatocyte (hep.) repopulation are given. All animals used in the study are shown: n 5 112 (rAAV3B), n 5 1 (rAAV8), n 5 212 (rAAV-LK03). c, In vivo comparisons between hFRG animals transduced with 5 3 10 11 vg rAAV8 or rAAV-LK03. Representative histological images are shown. Cell counting was as in Fig. 1a 
setting and thus maintained a more physiological gene expression profile compared with an in vitro setting. This made selecting a candidate useful in humans more likely. A summary of the transduction efficiencies of standard and newly selected AAV capsids described here is shown in Extended Data Table 3 . Taken together, the rAAV-LK03-based vector is not only a highly promising clinical candidate, but will also prove useful when restricted genetic manipulation of xenotransplanted cells/tissues is required. Most importantly, our studies suggest that the use of a human primary cell xenotransplant model compared with commonly used mouse and non-human primate models may more accurately predict potential transduction efficiency in humans. The approach provided herein may accelerate the ability to identify and establish clinically useful AAV vector candidates for clinical trials in which current serotype selection is in large part based on gene transfer efficiency in animal models.
METHODS SUMMARY
An AAV capsid library derived from ten different capsids was generated as previously described 14 , with minor modifications. The library was subsequently injected into FRG mice reconstituted with primary human hepatocytes 13 . Twenty-four hours later, wild-type hAd5 was injected to induce replication of the AAV library in the human hepatocytes. Forty-eight hours after hAd5 injection, livers were harvested and analysed for capsid sequences by PCR and Sanger sequencing. These liver lysates were used for subsequent rounds of selection. Computer algorithms were designed for sequence comparisons and capsid of origin contribution analysis.
After four passages of the library, selected capsid clones were cloned into standard AAV vector production plasmids and then used to package various vector expression cassettes. rAAV-RSV-eGFP, RSV-Luc and hPGK-GFP-P2A-Luc expression cassettes packaged in various capsids were used in cell culture studies 14 . AAV-RSV-Luc and rAAV-LSP1-eGFP 30 were used in tumour xenotransplant and FRG in vivo studies, respectively. In the FRG mice, 1-2 weeks after vector infusion the number of human hepatocytes was determined by anti-human-albumin staining, and the transduced mouse and human cells were quantified by eGFP fluorescence 30 . In some animals, the number of proviral vector genomes in mouse versus human hepatocytes was determined by LCM and qPCR 30 . Author Information Reprints and permissions information is available at www.nature.com/reprints. The authors declare competing financial interests: details are available in the online version of the paper. Readers are welcome to comment on the online version of the paper. Correspondence and requests for materials should be addressed to M.A.K. (markay@stanford.edu).
METHODS
AAV library generation. The AAV library was generated as previously described 14 with minor modifications. AAV capsid genes (cap) from AAV1, 2, 3, 4, 5, 6, 8, 9, avian AAV and bovine AAV were PCR amplified and cloned into TOPO PCR Cloning Kit (Life Technologies) and sequenced. cap genes were cut out using PacI and AscI, mixed at a 1:1 ratio and digested using DNaseI (Roche) for 1, 5, 10, 15, 20, 25 and 30 min. All reactions were separated on 1% (w/v) agarose gel, and fragments ,1,000 bp were cut out and used in a primer-less PCR reassembly step, followed by a second round of PCR including primers binding outside the cap gene (forward primer 59-GTCTGAGTGACTAGCATTCG and reverse primer 59-GCTTACTG AAGCTCACTGAG) 14 . Final reassembled shuffled cap genes were cloned into the AAV recipient plasmid based on wild-type AAV2. The final ligations were transformed into 40 independent competent DH5a cell aliquots and plated on 100 15 cm Luria broth (LB)/agar plates. One-hundred clones were picked and sequenced to confirm library variability. The remaining clones were scraped, pooled and expanded in liquid LB plus ampicillin culture. Final library plasmid DNA was extracted using EndoFree Megaprep Kit (Qiagen) and used for AAV library production. AAV vectors and AAV library production. AAV library and AAV vectors were packaged as previously described using a Ca 3 (PO 4 ) 2 transfection protocol followed by CsCl gradient purification as described 14 . Vectors used in studies shown in Figs 1 and 4c were titred by qPCR as described 30 , whereas all other vectors used in the study were titrated by quantitative dot blot as described 31 . All AAV productions were performed using HEK293 cells (ATCC, catalogue no. CRL-1573). AAV library yielded a preparation with a particle titre of 2 3 10 12 vg ml 21 . Humanized FRG animals. Animal housing and all animal work was performed in accordance with the ethical guidelines for animal care at Stanford University and the Children's Hospital at Westmead (CHW) and Children's Medical Research Institute (CMRI) Animal Care and Ethics Committee. FRG 13 breeding pairs (M.G. laboratory) were used to establish FRG mouse colonies at Stanford University and the CMRI. To restrict the variability due to the host cells, all mice used during library selection were transplanted with fresh hepatocytes obtained from a single donor, a 52-year-old Caucasian female with a neuroendocrine tumour without chemotherapy treatment. Mice used in studies shown in Figs 1a and 4b were transplanted with cryopreserved primary hepatocytes (isolated by collagenase perfusion from paediatric donors or purchased from Invitrogen (catalogue no. HMCPIS, lot no. Hu8089) while mice used in studies shown in Fig. 4c were transplanted with cells isolated from paediatric donors or purchased from Lonza (catalogue no. CC-2591S, lot no. 9F3097 and 9F3003) (1 3 10 6 viable cells per mouse) as described 13 . This mouse model has been used for testing other specific human processes related to drug metabolism and infectious diseases 32 .
For studies shown in Figs 2a and 4b, only 8-12-week-old female mice were used for repopulation, whereas for studies shown in Figs 1 and 4c , both repopulated males and females were used. Twenty-four hours before hepatocyte transplantation, mice received intravenous (i.v.) injection of 5 3 10 10 plaque-forming units (p.f.u.) of human urokinase (uPA) adenoviral vector 33 . Each animal received 1 3 10 6 hepatocyte via intrasplenic injection. Mice received subcutaneous injections of the IL2R blocker (1.5 mg per animal per day) Kineret (Anakinra) for 7 days. 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) cycles were initiated 48 h after transplantations, as described 13 .
The progress of liver repopulation was monitored by biweekly human albumin ELISA using Human Albumin ELISA Quantitation Kit (Bethyl Labs, catalogue no. E88-129) and goat anti-human albumin HRP antibody (crossed adsorbed against bovine, mouse, pig) (Bethyl Labs, catalogue no. A80-229P, lot no. A80-229P-13) as per the manufacturer's instructions, with 1 mg ml 21 human albumin being equivalent to ,20% repopulation. Engrafted hepatocytes were allowed to expand before mice were transduced with rAAV; vector was injected 73-124 days after transplant (with a mean of 96 days after transplant). Human-hepatocyte-transplanted mice containing at least 5% human hepatocytes (for studies shown in Fig. 2a ), at least 10% (for studies shown in Fig. 1a ) and or at least 40% (for studies in Fig. 4b, c) were placed in separate cages with number tags. At the time of vector administration, the available mice were randomly picked out of the cage and treated sequentially with the various viruses/vector treatment groups. In vivo AAV library selection, AAV Cap PCR and AAV variant vectorization. FRG animals received 1 3 10 11 vg per animal AAV library via i.v.. injection followed by i.v. injection of wild-type human AD5 (VR-5; ATCC) 24 h later. Livers were harvested 48 h after hAd5 injection, minced and frozen in aliquots in liquid nitrogen. One aliquot was used for AAV purification. Sample was mixed with 23 volume PBS per weight (200 ml PBS per 100 mg tissue) and underwent three freeze-thaw cycles followed by tissue homogenization, hAd5 inactivation (65 uC for 30 min), and 5 min spin at 14,000g at 4 uC. The clear supernatant was used for subsequent in vivo selection step and PCR analysis. For PCR analysis, 1 ml of the supernatant was used for AAV DNA extraction using WAKO DNA Extraction Kit (WAKO), followed by PCR amplification (forward, 59-GATCTGGTCAATG TGGATTTG; and reverse, 59-ACCGCAGCCTTTCGAATGTCC). PCR was performed using KAPA HiFi HotStart ReadyMix (KAPA Biosystems) and the following program: 2 min 98 uC, 30 cycles of 20 s 98 uC, 15 s 55 uC, 72 uC 1 min. PCR product (2.3 kb) was cloned into TOPO PCR Cloning Kit (Life Technologies) and 1001 clones were sent for sequencing. Clones selected for vectorization were PCR amplified using customized oligonucleotides: forward, 59 -ACATTTAAAT CAGGTATGN27; and reverse, 59-GTTTAAACGAATTCGCCCTTCGCAGAG ACCAAAGTTCAACTGAAACGAATCAACCGGTTTATTGATTAACAGGCA ATTAN27 (start and stop codons of cap are shown in bold and N27 represents 27 nucleotides after ATG or preceding TTA for a given AAV clone), cloned into TOPO cloning kit, verified, released using AscI-PacI digestion and cloned in frame downstream of rep into predigested recipient pCap plasmid containing AAV2 rep without inverted terminal repeat (ITR) sequences. The variability of the final library was confirmed by sequencing 100 random clones and demonstrating that each clone had a unique sequence with extensive genetic diversity. Shuffled vector sequence analysis. AAV cap sequences obtained from TOPO cloning were analysed using Geneious 6.0.5 software (Biomatters). Geneious was used for DNA and protein sequence alignments and for reconstruction of the genealogical relationship among viral isolates. Shuffled AAV sequence contribution analysis. An in-house Perl pipeline was set up to analyse the results of sequence alignment by the NCBI BLAST suite (blastn and blastp). The pipeline generated the overall serotype composition of novel AAVs by comparison of DNA and amino acid sequences with their parent AAVs based on maximum likelihood. In vitro transduction analysis and transduction titre calculation. Cells were plated in 24-well tissue-culture-coated plates in appropriate media 16 h before transduction. Cells were transduced with AAV-RSV-GFP vectors at four tenfold dilutions for 16 h. GFP levels were analysed using fluorescence-activated cell sorting (FACS) using BD LSR II. The percentage of GFP 1 cells was used to calculate transduction titre (TU ml 21 ) by using the following formula: TU ml 21 5 (%GFP/ 100) 3 (cell number at transduction) 3 (dilution factor). Transduction titre was normalized to dot blot titre (vg ml 21 ). For each cell line, the vector with the lowest normalized transduction (TU vg 21 ) was assigned the value 1 and used as a basis for normalization of all other vectors. Primary human hepatocyte culture and transduction. Fresh primary human hepatocytes were plated on plates coated with rat tail Collagen Type II (BD Biosciences) in HMM Hepatocyte Maintenance Medium with UltraGlutamin-1 (Lonza). Cells were transduced with AAV-RSV-Luc (Extended Data Table 1 ) or rAAV-PGK-GFP-P2A-Luc2-pA (Fig. 3b ) vectors for 16 h. For the experiment shown in Fig. 3b , cells were transduced at the same multiplicity of infection (MOI) as the dot blot titre. Seventy-two hours after transduction, cells were washed in PBS and analysed using Dual-Luciferase Assay System (Promega) and Tecan M-1000 luminometer. Mycoplasma testing. All cell lines and primary cells used in the study underwent mycoplasma testing before use. Negative mycoplasma contamination status was verified using LookOut Mycoplasma PCR Kit (Sigma, catalogue no. MP0035) and MycoAlert Mycoplasma Detection Kit plus Assay Control (Lonza, catalogue no. LT07-318 and LT07-518). IVIG neutralization assay. IVIG neutralization assay was adopted from the previously described method 34 , with modifications. Two IVIG preparations, Gammagard S/D (Baxter/Hyland) (IgA content of 1.6 mg ml 21 in 5% solution) and Gamunex (Bayer) (IgA content of 46 mg ml 21 ), were initially compared side by side using Huh-7 cells (gift from J. Glenn). rAAV2-RSV-Luc2 vector was used as a positive control to establish IVIG neutralization assay. Two protocols were compared. AAV pre-incubation with IVIG at 4 uC overnight and 37 uC for 60 min. As shown in Extended Data Fig. 1 , both preparations showed a similar profile of AAV2 neutralization. For all future experiments, 60 min AAV pre-incubation with IVIG at 37 uC was used.
For the rAAV variants IVIG neutralization assay, an identical number of vector particles of the eight selected rAAV variants were incubated with increasing concentrations of Gammagard/Gamunex at 37 uC before Huh-7 cell transduction in DMEM media without FBS. Cells were washed 5 h later and allowed to grow for 72 h in DMEM plus 10% FBS (v/v). Cell were harvested and analysed for Luc expression (see earlier). hHGF competition assay. hHGF competition assay was performed as described previously 27 . Huh-7 cells were transduced with rAAV-PGK-GFP-P2A-Luc2 at MOI 2 3 10 4 . Vectors were premixed with increasing concentrations of recombinant HGF (Life Technologies). Cells were analysed for Luc levels 72 h after transduction (see earlier). In vivo hFIX expression and analysis. Six-to-eight-week-old female C57BL/6 mice (Jackson Laboratory) received retro-orbital injection of 5 3 10 10 vg rAAV-hFIX-16 vectors. Blood was collected at the indicated time points via retro-orbital bleeding, and plasma hFIX levels were determined using ELISA, as described 35 . 
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